Table 3.
Association of gestational age at first antenatal care visit with receipt of IPTp (regression results)
| No. of IPTp doses received | Gestational age at first antenatal care visit, OR (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|
| ≤12 Weeks (n = 4,061) | Month 4 (n = 2,343) | Month 5 (n = 1,952) | Month 6 (n = 1,156) | Month 7 (n = 541) | Month 8 (n = 172) | Month 9+ (n = 37) | Month 10+ (n = 6) | |
| 0 | Ref. | 0.656 (0.55–0.79), P = 0.00 | 0.708 (0.58–0.86), P = 0.00 | 0.765 (0.61–0.96), P = 0.02 | 0.785 (0.56–1.08), P = 0.14 | 1.238 (0.78–1.96), P = 0.36 | 1.319 (0.51–3.40), P = 0.57 | 1.689 (0.20–14.49), P = 0.63 |
| 1 | Ref. | 0.86 (0.75–0.98), P = 0.02 | 0.74 (0.64–0.86), P = 0.00 | 0.92 (0.78–1.09), P = 0.34 | 1.33 (1.07–1.64), P = 0.009 | 2.05 (1.47–2.88), P = 0.00 | 2.32 (1.17–4.63), P = 0.02 | 2.11 (0.35–12.67), P = 0.41 |
| 2 | Ref. | 0.79 (0.69–0.91), P = 0.001 | 0.85 (0.73–0.98), P = 0.03 | 1.10 (0.93–1.30), P = 0.28 | 1.62 (1.31–2.0), P = 0.00 | 1.42 (0.98–2.06), P = 0.06 | 2.28 (1.12–4.64), P = 0.02 | 2.76 (0.46–16.58), P = 0.27 |
| ≥3 | Ref. | 1.294 (1.16–1.45), P <0.001 | 1.372 (1.22–1.55), P <0.001 | 0.99 (0.86–1.14), P = 0.94 | 0.56 (0.46–0.68), P = 0.00 | 0.41 (0.29–0.58), P = 0.00 | 0.23 (0.10–0.50), P = 0.00 | 0.19 (0.02–1.72), P = 0.14 |
| Timing of first antenatal care visit, OR (95% CI) | |||
|---|---|---|---|
| ≤12 Weeks (n = 1,835) | 13–26 Weeks (n = 3,152) | 27–40 Weeks (n = 165)* | |
| ≥3 | Ref. | 1.21 (1.10–1.32), P = 0.00 | 0.46 (0.38–0.57), P = 0.00 |
This table presents five separate regression analyses (by month for zero, one, and two total doses, and by month and trimester for three or more total doses). IPTp = intermittent preventive treatment in pregnancy; IPTp3+ = three or more doses of intermittent preventive treatment in pregnancy; OR = odds ratio; Ref. = reference value. Values in bold type are statistically significant.
*
Third trimester.